6h agoSeeking AlphaBULLISH 76Product/PR
GRAIL sets new 52-week high as FDA panel backs cancer test
GRAIL (GRAL) stock hits a 52-week high after an FDA advisory panel backs Galleri, a multi-cancer blood test developed by the company. Read more here.
Archived explainer. For the current picture see today's GRAL page.
Why Is GRAIL INC EQUITY Equity (GRAL) Stock Up Today?
By the Top Tier Newswire AI Desk · September 24, 2026 at 2:07 PM ET · reviewed against 3 wire stories
GRAIL INC EQUITY Equity (GRAL) is up +11.81% in the latest session. Our newswire has captured 3 stories on GRAL across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 73/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why GRAL stock is up today
GRAIL Inc. (GRAL) surged 11.81% to $121.34 in intraday trading, marking a new 52-week high. The rally followed a favorable vote from a U.S. Food and Drug Administration (FDA) advisory panel, which endorsed the company’s Galleri multi-cancer early detection blood test. The panel determined there is reasonable evidence supporting the test’s effectiveness, a key development for GRAIL’s regulatory pathway.
What Happened
The FDA advisory committee’s vote came after a period of trading halt on Wednesday, which preceded the panel meeting. The halt ended with a resumption of trading and a sharp upward move. The stock had already gained 34% on Monday after the FDA released briefing documents that highlighted no significant safety concerns with the Galleri test. The panel’s endorsement of the test’s safety and effectiveness has been interpreted as a positive step toward potential regulatory clearance, which could expand GRAIL’s commercial opportunities.
The stock opened with a 4.1% gap up from the prior close and reached a session high of $121.99 before settling near $121.58. The move reflects strong investor optimism following the panel’s decision.
What The Data Shows
The stock has risen 53.2% over the last eight trading sessions, moving from $75.89 to $116.28. On September 24, it printed 28 fresh 52-week highs and two 52-week lows. Trading volume has been elevated, with 1.7 million shares traded so far, or 2.1 times the 3-month daily average. The stock is currently trading above its 52-week range of $41.50 to $118.84. Meanwhile, recent insider transactions show four sales totaling $7.5 million in the last 90 days, with the most recent filing on September 23.
What To Watch
Investors will be watching for further developments in the FDA’s formal decision process, which could influence the next phase of regulatory and commercial progress for GRAIL.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
GRAL by the numbers
Last: $121.34Session: +11.81%7 sessions: +53.22%Coverage: 3 stories / 2 sourcesAI sentiment: 73/100 (bullish)Mkt cap: $4.8B52w: $41.50 to $118.84
The headlines behind the move
21h agoSeeking AlphaBULLISH 76Product/PR
GRAIL's Galleri test wins endorsement from FDA panel
A panel of US FDA advisors voted that there is reasonable evidence that GRAIL’s (GRAL) multi-cancer early detection blood test Galleri is effective. The vote wa
23h agoStocktwits NewsBULLISH 67Product/PR
GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness
The stock has been on a trading halt on Wednesday ahead of the committee meeting, but it rallied 34% on Monday after the FDA posted briefing papers that flagged no particular concerns.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on GRAL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GRAL move explainers: 2026-09-24 · 2026-09-22 · 2026-09-21 · 2026-08-06